Tags

Type your tag names separated by a space and hit enter

Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
J Lipid Res. 2012 Nov; 53(11):2443-9.JL

Abstract

We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS). We studied 11 MetS men in a randomized, double-blind, crossover trial. VLDL-apoE kinetics were examined using stable isotope methods and compartmental modeling. Compared with placebo, fenofibrate (200 mg/day) and atorvastatin (40 mg/day) decreased plasma apoE concentrations (P < 0.05). Fenofibrate decreased VLDL-apoE concentration and production rate (PR) and increased VLDL-apoE fractional catabolic rate (FCR) compared with placebo (P < 0.05). Compared with placebo, atorvastatin decreased VLDL-apoE concentration and increased VLDL-apoE FCR (P < 0.05). Fenofibrate and atorvastatin had comparable effects on VLDL-apoE concentration. The increase in VLDL-apoE FCR with fenofibrate was 22% less than that with atorvastatin (P < 0.01). With fenofibrate, the change in VLDL-apoE concentration was positively correlated with change in VLDL-apoB concentration, and negatively correlated with change in VLDL-apoB FCR. In MetS, fenofibrate and atorvastatin decreased plasma apoE concentrations. Fenofibrate decreased VLDL-apoE concentration by lowering VLDL-apoE production and increasing VLDL-apoE catabolism. By contrast, atorvastatin decreased VLDL-apoE concentration chiefly by increasing VLDL-apoE catabolism. Our study provides new insights into the mechanisms of action of two different lipid-lowering therapies on VLDL-apoE metabolism in MetS.

Authors+Show Affiliations

Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22930812

Citation

Ooi, Esther M M., et al. "Effect of Fenofibrate and Atorvastatin On VLDL apoE Metabolism in Men With the Metabolic Syndrome." Journal of Lipid Research, vol. 53, no. 11, 2012, pp. 2443-9.
Ooi EM, Ng TW, Watts GF, et al. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. J Lipid Res. 2012;53(11):2443-9.
Ooi, E. M., Ng, T. W., Watts, G. F., Chan, D. C., & Barrett, P. H. (2012). Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. Journal of Lipid Research, 53(11), 2443-9. https://doi.org/10.1194/jlr.P029223
Ooi EM, et al. Effect of Fenofibrate and Atorvastatin On VLDL apoE Metabolism in Men With the Metabolic Syndrome. J Lipid Res. 2012;53(11):2443-9. PubMed PMID: 22930812.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. AU - Ooi,Esther M M, AU - Ng,Theodore W K, AU - Watts,Gerald F, AU - Chan,Dick C, AU - Barrett,P Hugh R, Y1 - 2012/08/28/ PY - 2012/8/30/entrez PY - 2012/8/30/pubmed PY - 2013/3/7/medline SP - 2443 EP - 9 JF - Journal of lipid research JO - J Lipid Res VL - 53 IS - 11 N2 - We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS). We studied 11 MetS men in a randomized, double-blind, crossover trial. VLDL-apoE kinetics were examined using stable isotope methods and compartmental modeling. Compared with placebo, fenofibrate (200 mg/day) and atorvastatin (40 mg/day) decreased plasma apoE concentrations (P < 0.05). Fenofibrate decreased VLDL-apoE concentration and production rate (PR) and increased VLDL-apoE fractional catabolic rate (FCR) compared with placebo (P < 0.05). Compared with placebo, atorvastatin decreased VLDL-apoE concentration and increased VLDL-apoE FCR (P < 0.05). Fenofibrate and atorvastatin had comparable effects on VLDL-apoE concentration. The increase in VLDL-apoE FCR with fenofibrate was 22% less than that with atorvastatin (P < 0.01). With fenofibrate, the change in VLDL-apoE concentration was positively correlated with change in VLDL-apoB concentration, and negatively correlated with change in VLDL-apoB FCR. In MetS, fenofibrate and atorvastatin decreased plasma apoE concentrations. Fenofibrate decreased VLDL-apoE concentration by lowering VLDL-apoE production and increasing VLDL-apoE catabolism. By contrast, atorvastatin decreased VLDL-apoE concentration chiefly by increasing VLDL-apoE catabolism. Our study provides new insights into the mechanisms of action of two different lipid-lowering therapies on VLDL-apoE metabolism in MetS. SN - 1539-7262 UR - https://www.unboundmedicine.com/medline/citation/22930812/Effect_of_fenofibrate_and_atorvastatin_on_VLDL_apoE_metabolism_in_men_with_the_metabolic_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-2275(20)41261-1 DB - PRIME DP - Unbound Medicine ER -